Drug Trial Radar · NCT07950930
DAX-044 in Adults With Advanced Solid Tumours: a First-in-human Study of Safety, Dose and Early Anti-cancer Activity.
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
142
Planned (sponsor's estimate)
Start
Feb 1, 2027
Primary completion
Aug 10, 2030
Study completion Oct 23, 2030
Sponsor
- Lead sponsor
- Audax Biosciences Pty. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human, multicentre, Phase 1, open-label study designed to evaluate the safety and tolerability of DAX-044 as monotherapy, and to determine its maximum tolerated dose, in adults with advanced solid tumours.
Conditions
- Advanced Solid Tumours
Interventions
DAX-044Drug
DAX-044 monotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs) as Assessed by CTCAE v6.0Time frame: Up to 24 months
- Maximum Tolerated Dose (MTD) of DAX-044 Based on Dose-Limiting Toxicities (DLTs) (Part 1)Time frame: Up to 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Linear Clinical Research Ltd
Nedlands, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.